#USA #Chicago #Seegene #CURECA™ #STAgora™

Seegene Unveils Groundbreaking Technologies at ADLM 2025

Seegene Inc., a global leader in molecular diagnostics, has made significant strides in laboratory automation with the introduction of the CURECA™ automation system and STAgora™ data analysis platform at the ADLM 2025 conference held in Chicago from July 29 to 31. These two cutting-edge technologies aim to transform the diagnostic landscape by enhancing efficiency and precision in infectious disease monitoring.

Pioneering Fully Unattended PCR Automation

At the center of Seegene's showcase is CURECA™, the world’s first fully unattended automation system for PCR testing. This innovative product is designed to automate every stage of the PCR process, specifically addressing the traditionally manual preprocessing phase. Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, emphasized that CURECA™ is pivotal for freeing laboratories from the limitations imposed by manual processes, integrating seamlessly to allow round-the-clock operations.

CURECA™ fulfills three essential requirements for true automation: it operates without the need for highly trained professionals, can process samples continuously 24/7, and allows uninterrupted specimen input. The system’s CURECA™ Prep module efficiently handles various sample types, including urine, blood, sputum, and stool, which are typically challenging for automation solutions. By managing the diverse preprocessing of samples, CURECA™ enables a complete PCR workflow from sample insertion to nucleic acid extraction, amplification, and result analysis without manual intervention.

This game-changing approach enhances efficiency and reduces human error within laboratories, allowing skilled personnel to focus on higher-value tasks instead of repetitive procedures. Seegene's vision extends beyond current applications; CURECA™ Prep has the potential to expand into other testing areas, including clinical chemistry and immunodiagnostics.

Real-time Data Analysis with STAgora™

Complementing CURECA™, Seegene introduced STAgora™, a dynamic platform for real-time analysis of PCR test data. STAgora™ is designed to provide laboratories with an extensive context for interpreting diagnostic procedures through its array of over 40 analytical tools. These tools facilitate infection trend tracking, positivity monitoring at the hospital level, and co-infection analysis of multiple pathogens.

Unlike traditional data repositories, STAgora™ offers integrated solutions, allowing hospitals to create their own statistical datasets and compare aggregate data across institutions. This capability accelerates the identification of infection patterns and promotes informed decision-making in clinical settings. Furthermore, the data shared through STAgora™ is anonymized and formatted according to institutional requirements, ensuring secure and real-time information exchange on local, national, or global scales.

Moving Towards a Disease-Free World

Dr. Chun reiterated Seegene's long-term goal of building a “disease-free world.” The introduction of CURECA™ and STAgora™ complements the company’s foundational technological pillars, which include its proprietary PCR technology and the Seegene Digitalized Development System (SGDDS) for automated test development. As industry experts exhibited keen interest during the presentation at ADLM 2025, insights from prominent figures like Jamel Giuma peak a testament to CURECA™’s revolutionary potential in streamlining laboratory workflows and significantly boosting operational efficiency.

In conclusion, Dr. Chun remarked, “With CURECA™ and STAgora™, we are overcoming enduring barriers in molecular diagnostics. Just as smartphones and electric vehicles have transformed their industries, we believe these technologies will redefine the possibilities of diagnostic testing, enabling labs globally to achieve genuine automation, unlock the value of diagnostic data, and ultimately contribute to constructing a world free of diseases.”

Disclaimer: The technologies CURECA™ and STAgora™ showcased at ADLM 2025 are still under development and are not commercially available or approved for clinical diagnostic use in any jurisdiction.